Check out our most popular compounded medications! Get Started
Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules are crafted with Methocel E4M, a controlled-release polymer. This ensures a gradual release of the active ingredients, offering sustained therapeutic effects. The formulation is beneficial for treating conditions like Ulcerative Colitis, Crohn's Disease, Proctitis, Proctosigmoiditis, and Diverticulitis. The slow release mechanism enhances medication efficacy and improves patient compliance by reducing dosing frequency.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules is a meticulously compounded medication, primarily used in the treatment of various inflammatory diseases such as ulcerative colitis, Crohn's disease, and proctitis. This unique formulation synergistically combines mesalamine, a potent anti-inflammatory agent, with sodium butyrate, a beneficial short-chain fatty acid. The result is a slow-release medication that ensures a steady and prolonged release of the active ingredients, thereby providing a consistent therapeutic effect over an extended period.
The encapsulation of these active ingredients is achieved using Methocel E4M, a specialized controlled-release polymer. This advanced technology is designed to gradually release the encapsulated medication, offering sustained therapeutic effects. This slow-release mechanism not only enhances the efficacy of the medication but also reduces the dosing frequency, thereby improving patient compliance, particularly for medications requiring a controlled and prolonged release profile.
Research has demonstrated the effectiveness of the combination of mesalamine and sodium butyrate in reducing inflammation and alleviating the symptoms associated with these inflammatory diseases. Furthermore, this formulation is generally well tolerated by patients, with minimal side effects reported.
At Bayview Pharmacy, we are dedicated to providing our patients with the highest quality compounded medications. We understand that each patient is unique, and therefore, we strive to provide personalized medication solutions to meet individual health needs. If you have any questions about this formulation or any other compounded medications, we encourage you to reach out to us. Our team of experienced pharmacists is always ready to assist you with your medication needs.
Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules is a compounded medication designed to treat conditions such as ulcerative colitis, Crohn's disease, and other inflammatory bowel diseases. The medication works by reducing inflammation in the intestines, providing relief from the symptoms associated with these conditions.
This formulation is encapsulated with Methocel E4M, a controlled-release polymer. This technology allows for the gradual release of the active ingredients over an extended period, providing sustained therapeutic effects. This slow-release mechanism can lead to reduced dosing frequency, potentially improving patient compliance, particularly for those requiring a controlled and prolonged release profile.
It is important to note that this medication is not recommended for use in children under the age of 18. Patients who are pregnant, planning to become pregnant, or breastfeeding should inform their healthcare provider before starting this medication. Additionally, patients should disclose any other medications they are currently taking, including prescription and over-the-counter medications, vitamins, and herbal supplements, as Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules may interact with other medications, including antacids, antibiotics, and diuretics.
Patients with a history of kidney disease, liver disease, or any other medical condition should not take Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules without first consulting their healthcare provider. It is also crucial to inform the healthcare provider of any allergies to any of the ingredients in this medication.
It is essential to take Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules exactly as prescribed by the healthcare provider. Patients should not alter the dosage or duration of the medication without professional medical advice. If you have any questions or concerns about this medication, please consult your healthcare provider.
Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules is a compounded formulation specifically designed for the treatment of ulcerative colitis, a type of inflammatory bowel disease. This combination medication works synergistically, with mesalamine reducing inflammation in the colon and sodium butyrate aiding in the reduction of inflammation and enhancing the absorption of mesalamine. The unique feature of this formulation is its slow-release mechanism, which is achieved through the use of Methocel E4M, a controlled-release polymer. This allows for the gradual release of the encapsulated medication over an extended period, providing sustained therapeutic effects and improved patient compliance. The reduced dosing frequency not only enhances the effectiveness of the treatment but also improves patient adherence to the medication regimen. The capsules are to be taken orally, with or without food, as per the doctor's instructions. It is crucial to adhere to the prescribed dosage and not to miss any doses to ensure the effectiveness of the treatment. Potential side effects may include nausea, vomiting, or abdominal pain. If any of these or other side effects occur, it is important to contact your healthcare provider immediately. This formulation is designed to provide a controlled and prolonged release profile.
Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules are a compounded formulation designed to provide sustained therapeutic effects over an extended period of time. This is achieved through the use of Methocel E4M, a controlled-release polymer that gradually releases the encapsulated medication or active ingredient. This slow-release mechanism reduces the need for frequent dosing and improves patient compliance, particularly for medications that require a controlled and prolonged release profile.
This formulation is primarily used in the treatment of inflammatory bowel diseases such as ulcerative colitis. However, it may also be beneficial in managing other conditions such as microscopic colitis, pouchitis, and ischemic colitis. Furthermore, it has potential applications in the treatment of radiation colitis, ulcerative jejunoileitis, and Behcet's disease.
Beyond gastrointestinal disorders, Mesalamine 50 mg/Sodium Butyrate Slow Release Ar Capsules may also be used in the management of certain rheumatic conditions. These include ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. However, it is important to note that this formulation is not recommended for use in children under the age of 18.
If you have any questions about the use of this formulation for any of these conditions, it is recommended to consult with a healthcare professional. They can provide guidance based on your specific health situation and needs.
This is a compounded formulation of two active ingredients, Mesalamine and Sodium Butyrate, encapsulated in a controlled-release polymer called Methocel E4M. The capsule is designed to gradually release the medication over an extended period of time.
Methocel E4M is a type of controlled-release polymer. It is used in the formulation to ensure that the active ingredients are released gradually over time. This offers sustained therapeutic effects and reduces the frequency of dosing.
A slow-release formulation offers several benefits. It provides sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, especially for medications that require a controlled and prolonged release profile.
The slow-release mechanism works by gradually releasing the encapsulated medication or active ingredient over an extended period of time. This is achieved through the use of a controlled-release polymer, Methocel E4M, in the formulation of the capsule.
The capsule contains 50 mg of Mesalamine and an unspecified amount of Sodium Butyrate. The exact dosage will depend on the patient's condition and should be determined by a healthcare professional.
Due to the slow-release formulation, the frequency of dosing is reduced. However, the exact dosing schedule should be determined by a healthcare professional based on the patient's condition.
This medication is typically prescribed for patients who require a controlled and prolonged release of Mesalamine and Sodium Butyrate. However, it should only be taken under the supervision of a healthcare professional.
As with any medication, there may be potential side effects. Patients should consult with their healthcare provider for detailed information.
Interactions may occur when this medication is taken with other drugs. It is important to inform your healthcare provider about all the medications you are currently taking.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Do not double the dose to catch up. Always consult with your healthcare provider for more detailed instructions.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
